The past few years have been challenging for the biotech.
Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now.
Antibiotic resistance is racing toward a global crisis, with “superbugs” projected to cause over 10 million deaths annually ...
The company could finally be ready to deliver on years of promise.
CRISPR Therapeutics (NASDAQ:CRSP) executives highlighted progress across its oncology and autoimmune cell therapy pipeline ...
MarketBeat on MSN
CRISPR Therapeutics gains after earnings as pipeline hope grows
CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings ...
CRISPR Therapeutics' CASGEVY gene-editing therapy targets severe SCD and TDT. Click here to read why CRSP stock is rated as a Buy.
CRISPR Therapeutics (NasdaqGM:CRSP) reports significant progress in the commercial rollout of Casgevy, its approved gene editing therapy for sickle cell disease. Patient initiations for Casgevy have ...
A sales partner offered a ray of hope that this company couldn't for itself.
Muscles make up nearly 40% of the human body and power every move we make, from a child's first steps to recovery after ...
CRISPR Therapeutics AG CRSP on Friday reported its fourth-quarter and full-year 2025 financial results, highlighting ...
Nobel laureate Jennifer Doudna, PhD; Matthew Porteus, MD, PhD, and Rodolphe Barrangou, PhD—offer their views on the commercial potential and challenges of genome editing following a rollercoaster 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results